CLINICAL TRIALS PROFILE FOR HUMULIN U

All Clinical Trials for Humulin U

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00522210 ↗	Comparison of a Twice Daily Versus a Three Times Daily Insulin Regimen in Children With Type 1 Diabetes	Completed	University of Calgary	N/A	2008-03-01	The purpose of this study is to determine whether there is a difference in blood sugar control (as measured by hemoglobin A1c (HA1c)), in children given twice daily insulin injections incorporating a new long acting insulin analogue (detemir) compared to children using their current three times a day insulin injections (with intermediate and rapid acting insulin).
NCT00532766 ↗	Evaluating Pharmacokinetics and Pharmacodynamics of Jusline	Completed	King Saud University	N/A	2006-11-01	To evaluate the pharmacokinetic and pharmacodynamic profile of a new human insulin (Jusline) after subcutaneous administration, and to compare this profile with Humulin insulin.
NCT00646581 ↗	Effect of Single Dose Intranasal Insulin On Cognitive Function	Completed	University of Massachusetts, Worcester	Phase 4	2006-10-01	The purpose of the study is to find out how a small dose of insulin might affect memory, the ability to concentrate, and improve your daily functioning in patients with schizophrenia and schizoaffective disorders. Insulin is not being used to treat diabetes in this study. The investigators propose a single dose, double-blinded, placebo-controlled trial of intranasal insulin in 40 subjects with schizophrenia or schizoaffective disorder to examine insulin's effect on cognition. The specific aims include: 1. Examine the effects of single doses of 40 IU intranasal insulin compared to placebo on cognitive functioning, including attention and memory. 2. Examine whether single dose of intranasal insulin administration will raise serum insulin level and decrease plasma glucose level Insulin will be delivered through an air spray pump into your nose. The investigators will be comparing one dose of insulin (40 International Units) with placebo, an inactive liquid.
NCT00657930 ↗	Observational Study in Type 2 Diabetes Treated by an Intensive Insulin Treatment (ICT) Containing Once Daily Levemir® (Insulin Detemir)	Completed	Novo Nordisk A/S		2008-03-01	This study is conducted in Europe. The aim of this observational study is to gain practical experience with once-daily Levemir administration in type 2 diabetes patients who were previously treated with Insulatard®, Humulin® N (NPH insulins) as basal insulin as part of their ICT under normal clinical practice conditions in Hungary.
NCT00705536 ↗	Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20	Completed	Halozyme Therapeutics	Phase 1	2007-12-01	The purpose of the study is to compare the pharmacokinetics (PK) and pharmacodynamics (PD) of Humalog (insulin lispro) or Humulin-R (recombinant human insulin) when administered as a single subcutaneous (SC) injection of 20 units (U) with or without coadministration of recombinant human hyaluronidase PH20 (rHuPH20). The study hypothesizes that the time required to reach maximum insulin concentration (tmax) when insulin is administered with rHuPH20 will be comparable or shorter than the time required without rHuPH20.

Clinical Trial Conditions for Humulin U

Condition Name

Condition Name for Humulin U
Intervention	Trials
Type 2 Diabetes Mellitus	5
Diabetes Mellitus, Type 2	4
Type 1 Diabetes Mellitus	4
Hyperglycemia	3

Condition MeSH

Condition MeSH for Humulin U
Intervention	Trials
Diabetes Mellitus	18
Diabetes Mellitus, Type 2	11
Diabetes Mellitus, Type 1	9
Hyperglycemia	3

Clinical Trial Locations for Humulin U

Trials by Country

Trials by Country for Humulin U
Location	Trials
United States	24
Italy	10
India	7
Canada	4
Germany	3

Trials by US State

Trials by US State for Humulin U
Location	Trials
California	7
Texas	3
Minnesota	2
Arizona	2
Pennsylvania	1

Clinical Trial Progress for Humulin U

Clinical Trial Phase

Clinical Trial Phase for Humulin U
Clinical Trial Phase	Trials
PHASE1	3
Phase 4	7
Phase 3	2

Clinical Trial Status

Clinical Trial Status for Humulin U
Clinical Trial Phase	Trials
Completed	26
Recruiting	3
Not yet recruiting	2

Clinical Trial Sponsors for Humulin U

Sponsor Name

Sponsor Name for Humulin U
Sponsor	Trials
Halozyme Therapeutics	4
Mayo Clinic	2
Geropharm	2

Sponsor Type

Sponsor Type for Humulin U
Sponsor	Trials
Other	38
Industry	17
NIH	1

Last updated: April 25, 2026

Humulin U (insulin human): What clinical-trial signals exist, and what is the market outlook?

What is Humulin U in regulatory and commercial terms?

Humulin U is an insulin human product (U-100) marketed by Eli Lilly and Company. It is part of the long-standing U.S. insulin franchise that includes multiple Humulin SKUs (e.g., NPH, R, U-100 Regular, U-100 NPH variants) and newer insulin competitors.

Clinical-trial posture: For legacy insulin molecules, most contemporary activity is not new-molecule phase work. Trial work typically shifts to comparative delivery systems, device/pen usability, switching studies, and real-world effectiveness rather than de novo efficacy for the same active ingredient.

Implication for trial search and forecasting: For Humulin U specifically, the main commercial question is not whether the molecule is clinically “new,” but whether formulation presentation, substitution dynamics, and payer coverage change net unit demand.

---

What clinical-trial updates apply to Humulin U now?

No complete, molecule-specific, time-bounded clinical-trial update set can be stated here without a verifiable registry record tied uniquely to “Humulin U” as a product identity (including manufacturer, presentation, and strength).

Because the request requires a clinical trials update with actionable content, this answer contains no trial listings, dates, or endpoints.

---

What is the market baseline for human insulin (U-100) products?

Humulin U sits in the “human insulin” market segment, which competes against two main categories:

1. Human insulin biosimilar/generic equivalents where allowed by substitution rules, procurement contracts, and payer policy.
2. Rapid-acting and long-acting insulin analogs (e.g., lispro, aspart, glargine, detemir, degludec) that typically capture higher share where formulary access and total cost of care favor analogs.

Commercial reality for legacy human insulin:

• Demand tracks type 1 and type 2 diabetes volumes, but share shifts depend on plan design, step edits, copay caps, and rebates.
• Unit pricing compresses relative to analogs in many markets, even if gross-to-net remains protected by contracting and channel structure.

Where Humulin U tends to fit:

• Patients requiring U-100 insulin human or who remain on it due to clinician familiarity, insurance coverage, or formulary restrictions.
• Settings that favor standardized regimens where dosing stability and cost drive procurement.

---

How should Humulin U market projection be modeled? (Decision-ready framework)

This projection framework is the highest-signal way to forecast Humulin U because it does not rely on molecule innovation, which is not typically present for a legacy human insulin.

Projection drivers

• Formulary access: whether human insulin remains a preferred tier vs analog-first.
• Substitution and contracting: pharmacy benefit manager (PBM) switching behavior and wholesaler procurement patterns.
• Patient persistence: churn from human insulin to analogs (and vice versa) after coverage changes.
• Pricing and reimbursement: rebates, government program pricing, and patient out-of-pocket design.
• Competition intensity: biosimilar availability and SKU breadth from other manufacturers.

Scenario structure (recommended)

Use three scenarios grounded in insulin market dynamics:

1. Base case: Humulin U share stays stable within human insulin but analog share continues to pressure overall insulin mix. Net sales grow at or slightly below diabetes population growth due to pricing normalization.
2. Downside: tighter payer access to analogs reduces human insulin volume faster than expected and increases share loss; net revenue declines or stagnates.
3. Upside: enhanced procurement preferences for human insulin (often driven by budget controls) improves share and protects volume even as total insulin demand rises.

---

What market data can be cited here for Humulin U?

No verifiable unit sales, prescription counts, or revenue figures specific to Humulin U are provided in the available context of this request.

Because the answer must be data-dense and citation-backed, this section cannot include numbers without a direct source.

---

Where is competitive pressure highest for Humulin U?

Humulin U faces the most pressure in:

• Commercial formularies where insulin analogs are preferred and patients switch to reduce hypoglycemia risk and simplify dosing.
• PBM-driven formulary management that accelerates conversion to analog preferred products.
• Tender and large-institution contracting where analogs may be priced competitively via rebates.

Humulin U retains resilience where:

• Human insulin remains on preferred tiers due to budget impact.
• Clinician and patient inertia sustains continuity of therapy.
• Coverage rules allow human insulin with minimal barriers.

---

What does this mean for near-term outlook?

A defensible near-term outlook for Humulin U depends on payer behavior rather than clinical innovation. In practical terms:

• Volume growth is tied to diabetes incidence and persistence.
• Revenue growth is constrained by pricing compression versus analogs and by net price erosion from competitive procurement.
• Share is the key lever: the product’s fate turns on whether PBMs and plans keep human insulin broadly preferred or pivot to analog-first pathways.

---

Key Takeaways

• Humulin U is an insulin human U-100 product in a legacy molecule category where trial activity typically shifts away from de novo efficacy and toward comparative or real-world evidence.
• This response contains no molecule-specific clinical trial update because no registry-level, product-unique information is provided in the input context.
• Market projection for Humulin U should be modeled through formulary access, substitution contracting, persistence, and pricing/rebate dynamics, not through new clinical signals.
• Competitive pressure comes primarily from insulin analog penetration and PBM formulary design; resilience depends on how human insulin is positioned in preference tiers.

---

FAQs

1. Is Humulin U a new insulin molecule?

No. It is a legacy insulin human product (U-100) rather than a new mechanism or new-generation insulin.

2. What type of clinical trials typically matter for legacy human insulin products?

Comparative studies tied to presentation or switching, plus observational evidence. For this request, no verified Humulin U-specific trial dataset is provided.

3. What most affects Humulin U revenue in the near term?

Payer formulary status, PBM switching behavior, rebates, and patient persistence, since the drug’s mechanism is established.

4. How does analog insulin competition change Humulin U demand?

Analog-first formularies usually reduce human insulin share over time, even if total insulin use rises.

5. What is the cleanest forecasting method for Humulin U?

Scenario modeling based on access (preferred vs nonpreferred), share drift to analogs, and net price trends from contracting rather than relying on innovation-led growth.

---

References

[1]